• Bird Rock Bio Files IND for Study of Nimacimab for Renal Diseases americanpharmaceuticalreview
    June 05, 2020
    Bird Rock Bio announced the Company has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a phase 2 clinical study of nimacimab, also known as RYI-018 ...
PharmaSources Customer Service